Questioning Stivarga’s Cost-Effectiveness In Colon Cancer

The high cost of colon cancer drugs is once again under fire, this time with Bayer and Onyx in the hot seat. In a Lancet editorial accompanying pivotal trial results for regorafenib, U.K. authors doubt the modestly efficacious drug will ever prove cost-effectiveness in colon cancer, but that its role in GIST looks more compelling.

The modest efficacy and toxic effects of Bayer AG/Onyx Pharmaceuticals Inc.’s Stivarga (regorafenib) suggest the drug is unlikely to be cost-effective in advanced colon cancer, according to an editorial in the Lancet, in what is becoming a familiar refrain in the crowded, expensive treatment space.

The Nov. 22 editorial, written by U.K. oncologists, comes as the drug is under review in Europe for metastatic colorectal...

More from Clinical Trials

More from R&D